Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: BiondVax Pharmaceuticals Ltd. BVXV

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.

BiondVax (NASDAQ: BVXV), a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment

Modern-day medicine has been revolutionized and personalized to cater to more specific disease characteristics. A prime example of this innovation is monoclonal antibodies (“mAbs”) and nanosized antibodies (NanoAbs), therapeutic options that address diseases in ways other therapies cannot. Several companies … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is featured in a recent Aegis Capital Corp. research report. Aegis titled the report “Good … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is planning a rapid development path that leverages the company’s expertise and capabilities in biological … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q2 Financial Report, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its financial results for the second quarter ended June 30, 2023; the … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Granted Extension to Regain NASDAQ Compliance

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, received an extension from NASDAQ to regain compliance with listing rules. The extension, which is … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment

M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

According to Goldman Sachs Research, the global pharmaceutical industry is sitting on about $700 billion in dealmaking firepower, expected to fuel M&A-driven growth as companies look to revamp their intellectual property portfolio as their existing patents expire (https://ibn.fm/7VNq6). Flush with … Continue reading

Posted in BiondVax Pharmaceuticals Ltd. BVXV | Leave a comment